Osmotica Pharmaceuticals plc Reports Third Quarter 2019 Results
Third quarter 2019 total revenue of $65.5 million Submitted NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid, to FDA BRIDGEWATER, N.J, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Osmotica …